1. Gut-brain axis: A cutting-edge approach to target neurological disorders and potential synbiotic application
- Author
-
Sumel Ashique, Sourav Mohanto, Mohammed Gulzar Ahmed, Neeraj Mishra, Ashish Garg, Dinesh Kumar Chellappan, Timothy Omara, Shabnoor Iqbal, and Ivan Kahwa
- Subjects
Microbiota-gut-brain axis ,Neurological diseases ,Probiotics ,Pathological perspectives ,Synbiotics ,Short chain fatty acids (SCFAs) ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
The microbiota-gut-brain axis (MGBA) represents a sophisticated communication network between the brain and the gut, involving immunological, endocrinological, and neural mediators. This bidirectional interaction is facilitated through the vagus nerve, sympathetic and parasympathetic fibers, and is regulated by the hypothalamic-pituitary-adrenal (HPA) axis. Evidence shows that alterations in gut microbiota composition, or dysbiosis, significantly impact neurological disorders (NDs) like anxiety, depression, autism, Parkinson's disease (PD), and Alzheimer's disease (AD). Dysbiosis can affect the central nervous system (CNS) via neuroinflammation and microglial activation, highlighting the importance of the microbiota-gut-brain axis (MGBA) in disease pathogenesis. The microbiota influences the immune system by modulating chemokines and cytokines, impacting neuronal health. Synbiotics have shown promise in treating NDs by enhancing cognitive function and reducing inflammation. The gut microbiota's role in producing neurotransmitters and neuroactive compounds, such as short-chain fatty acids (SCFAs), is critical for CNS homeostasis. Therapeutic interventions targeting the MGBA, including dietary modulation and synbiotic supplementation, offer potential benefits for managing neurodegenerative disorders. However, more in-depth clinical studies are necessary to fully understand and harness the therapeutic potential of the MGBA in neurological health and disease.
- Published
- 2024
- Full Text
- View/download PDF